Survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.
Abstract No : 2513
Abstract Type : Poster Discussion Session
Indication : Glioblastoma Multiforme
Intervention : MDNA55
Company : Medicenna Biopharma
Technology : Interleukin-4 Receptor (IL4R)
44 subjects comprise the MDNA55 per protocol analysis population: median age 56 (35 - 77); median dose 177 mg (range 18 – 240 mg), 50% had KPS # 80. No systemic toxicities observed, drug-related AEs were primarily neurological and characteristic of GBM, no deaths attributed to MDNA55. Median OS was 11.6 months (95% CI 7.9 – 15.2). When stratified by IL4R expression, mOS in IL4R High (n = 21) was 15 vs. 8.4 months in IL4R Low (n = 19); p = 0.2175. OS12 is 57% vs. 33%. When compared to the SCA (n = 81), MDNA55 subjects survived significantly longer: mOS 12.4 vs. 7.7 months; p = 0.0077. When comparing IL4R High groups, mOS in MDNA55 (n = 21) was 15.8 vs. 6.2 months in the SCA (n = 17); p = 0.0626. Subgroup analysis in unmethylated MGMT subjects also show better survival with MDNA55 (n = 23) than the SCA (n = 31); mOS 12.3 vs. 7.7 months (p = 0.0268), indicating that MDNA55 may be beneficial in patients resistant to temozolomide
MDNA55 subjects represent a difficult to treat population (de novo GBM, IDH wild-type, not eligible for surgery at recurrence). Single treatment with MDNA55 prolongs survival by nearly 10 months in a subset of rGBM expressing high levels of IL4R when compared to a matched SCA, providing an unprecedented outcome for this highly lethal disease
Subjects treated with MDNA55 (Interleukin-4 Receptor) represent a difficult to treat population (de novo GBM, IDH wild-type, not eligible for surgery at recurrence). Targeted therapies such as MDNA55 directed to IL4R may improve patient outcomes and help in selection of patients for future clinical trial. With MDNA55 survival increased by more than 7 months in IL4R high vs. IL4R low patients. MDNA55 may be beneficial in patients resistant to temozolomide.
Refer to Glioblastoma Multiforme Market report for detailed Insights.